ASX Announcement
29 October 2024

Q1 FY25 QUARTERLY ACTIVITIES REPORT & APPENDIX 4C

Continued Strong Sales & Clinical Adoption in Australia. First Orders of MetaXplore in the United Kingdom, Post Quarter End.

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a company at the forefront of microbiome diagnostics & therapeutics, is pleased to provide a summary of its activities for the quarter ended 30 September 2024.

Key Highlights

- **Financial Performance**[1]
  - **Cash receipts of $5.07m, up 184% vs Previous Corresponding Period (PCP)**
  - **Revenue of $3.65m, up 239% vs PCP**
    - **Personal Testing & Supplements revenue of $3.39m, up 317% vs PCP**
    - **Research Testing revenue of $0.26m, down 1% vs PCP**

- **Testing Business**
  - **Australia: Continued strong sales momentum for MetaXplore**
    - **Q1 annualised run rate of 7,328 MetaXplore tests sold**
    - **Strong start in Q2, with October a record sales month as of the 25th, with a week left in the month**

  - **Australia: MetaPanel sales continuing to build across all major states through Sonic Healthcare (ASX: SHL) network. MetaPanel presented at Australian Gastroenterology Week 2024 (hosted by GESA)**



  - **United Kingdom: Invivo Clinical transitioning to a new growth phase in H2 FY25**
    - **Sales force doubled at end of quarter aligned to the growth strategy**
    - **MetaXplore access commenced in October 2024 with first orders already received**

- **Accelerating Growth Through Strategic Appointments**
  - **Eric Davis, Ex Abbott and Cochlear appointed as Chief Growth Officer**
  - **Chris Saad, Ex Uber appointed as Chief Product Officer**

- **$16.4m in Cash or Equivalents at 30 September 2024, with $6.0m expected from Microba's FY24 R&D Tax Incentive, which was lodged during the quarter and is expected to be received in Q2 FY25**

- **The Quarterly Investor Video Presentation is now available via the Company's Investor Hub where investors and stakeholders can ask questions of management via this link https://ir.microba.com/announcements**

[1] Financials are preliminary and unaudited

JOIN MICROBA'S INTERACTIVE INVESTOR HUB
For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit **ir.microba.com/welcome**

ASX Announcement
29 October 2024

Commenting on the quarter, Microba's CEO, Dr Luke Reid, said:

"We continued to deliver positive sales momentum for our testing business led by MetaXplore test sales in Australia"

"In the United Kingdom, Q1 results were impacted through an intentional focus of the team on actively preparing for MetaXplore access in the UK across August and September. Through that focus, the team successfully achieved first MetaXplore orders in the UK in October under an Early Access Program to key clinician accounts, and doubled the size of the sales force setting up for growth and full market access in 2025"

"Microba's Therapeutic Development Programs continue to advance aligned to plan. Actively advancing MAP 315 to a Phase 2 clinical trial to demonstrate clinical efficacy. Growth in data for our Immuno-Oncology program. Generating further data supporting the leads for our Autoimmune Program. Active in our global partnering efforts. The potential of our groundbreaking therapeutic platform, innovative pipeline, and assets is incredibly exciting for patients and our shareholders.

"We continue to attract world class talent to spearhead our growth momentum. The attraction of this calibre of top tier talent is testament to the quality of the organisation we have built, the significance of the global opportunity, and our conviction for future success and impact of Microba"

"Microba is intensively focused on executing its testing and therapeutic business strategies. This quarter's continued strong results demonstrate the traction we are gaining in the market, giving us great confidence and excitement for the growth ahead with an expected strong close to H1, and continued growth acceleration into H2."

TESTING BUSINESS

Strategic transfer of Research Services Business Unit

On 10 October 2024, Microba announced it had entered into an agreement for the strategic transfer of its non-core Research Services business unit to Clinical Microbiomics A/S (CMC), a Denmark headquartered, global contract research organisation (CRO) specialising in microbiome genetic and metabolic analysis to industry and academic institutions.

The transfer of Microba's Research Services business unit will allow Microba to allocate 100% of its testing operations and business development resources to the growth of its core diagnostic microbiome testing business. This reinforces Microba's commitment to growth through intensive focus and operational excellence.

Under the terms of the Transfer Agreement, Microba will receive:

- retained revenue payable to Microba from existing contracts assigned to CMC
- commission payments for existing contracts assigned to CMC to the extent performed by CMC for up to a four-year period after completion;
- commission payments for new contracts with existing customers transitioned to CMC to the extent performed by CMC for up to a four-year period after completion, and new customers referred by Microba to CMC; and
- potential milestone payments across the next four financial years.

As a result of the above, the potential revenue to be received by Microba under the Transfer Agreement is up to $3,000,000 across the next four financial years.

Refer to full announcement here

Refer to video with Dr Luke Reid discussing strategic rationale here

MetaXplore™ Gastrointestinal Disorder Test

Strategic clinician education and sales activities in Australia delivered continued growth. This growth was represented in tests sales and by growth in ordering clinicians counteracting reduced sales from high volume accounts impacted by the winter school holiday period.

Sales & Health Care Professional (HCP) Accounts:

Despite the seasonal softness of revenues in Q1 vs Q4 driven by July & September school holiday periods in Australia, MetaXplore saw strong growth compared to the prior comparable period.

	Q1 FY25	vs Q1 FY24 (PCP)	vs Q4 FY24 (QoQ)
Tests Sold	1,832	913, up 101%	1,835, 0%
Ordering Clinicians	487	269, up 81%	414, up 17%

Growth strategy

- Targeted sales and marketing activities focused on high prescribing potential clinicians
- Clinician education
- Key Opinion Leader engagement
- Utility studies and publications

Commercial Opportunity:

MetaXplore™ is the most comprehensive test available to support diagnosis and management of functional gastrointestinal disorders. It is estimated that total addressable market for the MetaXplore test in the United States alone is over US $9.5B [2].

MetaPanel™ - Gastrointestinal Pathogen Test

Through Q1 FY25, further progress was made to bring MetaPanel™, a world-first diagnostic test, to healthcare professionals and patients nationwide across Australia. Doctor referrals and sales continuing to build across the country. In collaboration with Sonic Healthcare (ASX: SHL), the team are continuing to drive active KOL engagement, evidence generation activities and utility publications to support clinician adoption.

National Market Development:

Assoc. Prof. Michael Wehrhahn from Douglass Hanly Moir, the Sonic Healthcare NSW branch, presented on "*An early review of MetaPanel™ a Diagnostic Metagenomic Gastrointestinal Pathogen Assay*" to a well-attended workshop during Australian Gastroenterology Week 2024 hosted by the Gastroenterological Society of Australia (GESA). This is the leading event of the year for Gastroenterologists.

This event was supported by direct sales activity in Adelaide, seeing the Microba team collaborate with Sonic's SA branch, Clinpath, across 20+ clinic visits totalling direct contact with 70+ clinicians.

Early Adoption and Sales:

Doctor referrals and sales continuing to build across the country, focused around the major east coast states New South Wales, Victoria and Queensland. The sales strategy remains focused on gastroenterology specialists and general practitioners (GPs). Through executing direct clinician engagement strategies, growing KOL relationships,

[2] Assessment of Medicare claims analysis for specific ICD codes related to people with Pain, Bloating or diagnosed with Irritable Bowel Syndrome in the absence of diarrhea in the United States. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis. Test pricing assumes minimum of US $416.78 (aligned to CPT code 57507) for the US, however it is expected that higher pricing opportunity may be available with strong clinical utility data.

active clinical utility studies and publications together with the Sonic Healthcare team, we expect adoption to translate into meaningful sales volume and revenues in FY25.

Commercial Opportunity:

MetaPanel™ is a world-first NATA accredited test for diagnosing gastrointestinal pathogens. It is the most comprehensive gastrointestinal pathogen test available detecting both common and difficult-to-identify pathogens capable of causing infection. It is estimated that the total global addressable market for the MetaPanel test is over US $9B[3].

United Kingdom business, Invivo Clinical

The fundamental investment thesis of the Invivo Clinical acquisition was the ability to accelerate Microba's entry of its world leading MetaXplore™ test into the United Kingdom through an established team and customer base.

The UK market demand and anticipation for access to MetaXplore has been compelling since the acquisition was announced, and the team have now commenced MetaXplore testing access in the UK in October with first orders already received, setting up for full market access in 2025.

Supporting the UK growth strategy, the Invivo sales force was doubled at the end of the quarter.

Sales & HCP Accounts:

The team's focus on executing the transition to MetaXplore had a temporary impact on EcologiX sales and clinician numbers during the quarter, coupled with the seasonal softness reflective of the UK summer holidays. Pleasingly, during October, the Invivo business is trading in line with expectations, and testing and supplements sales are ahead of September, back in line with non-summer months. This focus and investment are expected to translate into growth from MetaXplore sales in H2 FY25.

	Q1 FY25	vs Q1 FY24 (PCP)	vs Q4 FY24 (QoQ)
Sales	$2.1m	$2.3m, down 5%	$2.2m, down 4%
Tests Sold	1,740	2013, down 14%	1,934, down 10%
Supplements Sold	31,944	30,846, up 4%	31,833, up 0.5%
Ordering Clinicians	771	784, down 2%	826, down 7%

Growth strategy

Stage 0 – Complete, expected to impact results in Q3 FY25

Stage 0 Strategy: Bolster sales resourcing for the UK team with recruitment of new talent and experience to unlock latent growth potential

- Field sales force doubled

Stage 1 – Commenced, expected to impact results in H2 FY25

Stage 1 Strategy: Launch Microba's MetaXplore™ product into the UK to drive testing growth

- Early Access Program commenced providing select clinician accounts with access to order MetaXplore, and first orders already received.
- This Early Access Program will be progressively opened to more clinicians over the months ahead, supporting full market access in 2025

[3] Assessment of Medicare claims analysis for specific ICD codes related to people with Diarrhea of Unknown Etiology who receive molecular testing for gastrointestinal pathogens in the United States (US). Estimated US private and Medicaid patient numbers extrapolated from Medicare claims analysis. Estimated Australia (AU), United Kingdom (UK), Germany (DE), Italy (IT), Spain (ES) and France (FR) numbers extrapolated from the US data based on published prevalence and regional pathogen panel testing information. Test pricing assumes minimum of US $416.78 (aligned to CPT code 57507) for the US, and pricing for other countries based on Gastrointestinal panel pricing predicates in each country. This is viewed to be the minimum with the top pricing predicate at US $2126.20.

THERAPEUTICS BUSINESS

Inflammatory Bowel Disease Program – Advancing MAP 315 for Phase 2

The role of the microbiome in health and disease continues to draw widespread interest from both consumers and the scientific community.

During the quarter, further progress was made to advance lead drug candidate MAP 315 for a Phase 2 clinical trial. Partnering efforts are active.

Phase 2 trial plans

Further progress was made over the quarter to prepare for a Phase 2 clinical trial with regulatory and manufacturing (CMC) activities towards an investigation new drug (IND) submission.

Commercial Opportunity

In December 2023 Microba successfully completed a Phase 1, first in human clinical trial for lead drug candidate MAP 315.

Preclinical characterisation data, together with the Phase 1 clinical study results and feedback from Microba's medical advisory board provide strong positive support for continuing to advance the clinical development of MAP 315 for the treatment of UC.

MAP 315 is being developed for the treatment of UC, a debilitating form of Inflammatory Bowel Disease (IBD) with >50% of patients unable to achieve sustained remission with current standard of care. The market for UC treatment was valued at US$7.5b in 2020 and is forecast to grow to US$10.8b by 2030[4].

Microba's novel drug candidate MAP 315 was originally identified using the Company's data-driven Therapeutic Platform, demonstrating that this previously unidentified novel bacterial species is commonly observed in healthy individuals but consistently deficient in individuals with IBD, and in particular UC. Subsequent pre-clinical investigation of MAP 315 through both *in vitro* and *in vivo* models demonstrated that MAP 315 promotes epithelial restitution and mucosal healing – biological activities that are associated with disease remission but not adequately addressed through existing therapies. MAP 315 provides a compelling commercial opportunity to fill a key gap in the current standard of care for UC treatment and represents a potential novel treatment paradigm for patients living with this debilitating disease.

Immuno-Oncology Program – Clinical data and sample set grown to over 4,500 patients

During the quarter Microba's clinical data and sample set was grown to over 4,500 patients. These additional clinical insights provide a powerful data package in support of potential future clinical development.

Data growth

Through the national Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) study[5] Microba is capturing a large and diverse bank of patient specimens for cancer patients receiving treatment and enrolled in clinical trials. This has quickly grown to over 3,500 patient samples and is expected to be one of the largest clinical specimen resources with respect to the microbiome and cancer treatment. This resource adds to more than 1,000 patient samples Microba has previously analysed from internally recruited and published studies.

[4] https://www.nature.com/articles/d41573-021-00194-5 , https://www.alliedmarketresearch.com/ulcerative-colitis-market
[5] https://www.omico.com.au/prospect/

Commercial Opportunity

This program is targeting the development of a therapeutic to improve response rates in cancer patients receiving immune checkpoint inhibitor (ICI) therapy. Global ICI sales continue to grow, with Merck announcing sales of the market-leading drug Keytruda of US$25b for calendar year 2023[6].

There is an increasing body of literature supporting a key role for the microbiome in cancer[7]. Cancer immunotherapy, and more specifically ICIs have become standard of care for a range of tumour types. However, despite their impact on cancer treatment, up to 70% of patients do not respond to these drugs[8,9] leaving a large, underserved patient population. Differences in the microbiomes of responders and non-responders to ICI treatment have been observed in international studies, and treatment of the microbiome using faecal microbiome transplants has demonstrated the ability to turn ICI non-responders into responders[10,11].

Microba has compiled a clinical dataset of over 1,000 individuals treated with ICIs from prospective recruited studies and published human clinical trial data. Using the Company's data-driven Therapeutic Platform, this has enabled the Company to identify organisms that are commonly observed in ICI responders, but consistently deficient in ICI non-responders Subsequent pre-clinical investigation of these leads through both *in vitro* models and *in vivo* animal models has demonstrated that these organisms induce specific and targeted immune responses, and are able to significantly reduce tumour burden. A microbiome-based adjuvant therapy that increases response to these drugs has the potential to become standard of care across a range of cancers, and therefore represents a substantial commercial opportunity for Microba.

Autoimmune Disease Program – Successful completion of discovery program

During the quarter, leads from the discovery program were advanced through multiple pre-clinical validation models confirming their disease relevant activity. In addition, both internal work and external autoimmune expert engagement has advanced study plans towards selection of final target indications.

Pre-clinical validation

The 6 lead strains from the discovery program completed in Q4 were advanced through studies to examine impact on gut barrier integrity and JAK/STAT pathway inhibition, confirming their disease relevant activity. In addition, the strains were further characterised for manufacturability and safety.

Commercial Opportunity

In June 2024, Microba completed its lead discovery program in partnership with Ginkgo Bioworks (NYSE: DNA) identifying 6 leads which demonstrate significant Autoimmune Disease relevant activity.

The data generated through the discovery program provides strong biological validation for further investment in these assets to move into the next stage of development.

The goal of this program is to discover and develop novel treatments for autoimmune diseases such as lupus, psoriatic arthritis and certain autoimmune liver diseases. Microba's Autoimmune Disease program was established in partnership with Ginkgo Bioworks (NYSE: DNA) in FY22 following Ginkgo's strategic investment into Microba's IPO. Both parties in collaboration committed to a 2-year drug discovery program principally targeting autoimmune disorders. The partnership brought together Microba's unique ability to identify and isolate human gut bacteria associated with health together with the high-throughput microbial screening capabilities of Ginkgo, creating a powerful drug discovery workflow.

[6] https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/
[7] Sepich-Poore e al. (2021). *The microbiome and human cancer.* DOI: 10.1126/science.abc4552.
[8] Leonardi et al. (2020). *International Journal of Oncology*. DOI: 10.3892/ijo.2020.5088.
[9] Wolchok et al. (2017). *New England Journal of Medicine*. DOI: 10.1056/NEJMoa1709684.
[10] Baruch et al. (2020). *Science*. DOI: 10.1126/science.abb5920.
[11] Davar et al. (2021). *Science*. DOI: 10.1126/science.abf3363.

Functional changes in the microbiome have been unequivocally linked to a broad range of autoimmune disease[12][13] Autoimmune diseases are a family of more than 80 chronic and often life-threatening illnesses, which occur when the body's own immune system attacks the body's healthy cells, tissues and organs. Autoimmune conditions now impact around 5% of the population and their prevalence is rising[14]. The global market for autoimmune disease treatments was estimated to be US$198b in 2023 and forecast to grow to US$288b by 2028[15]. This program represents a compelling opportunity to identify a next generation of autoimmune therapeutics from the human microbiome.

Team appointments

Supporting our continued growth momentum, a number of recent appointments have been made.

Appointment of Chief Growth Officer – Eric Davis

Eric brings 35 years of experience in global commercial leadership roles across strategic planning, new product innovation, marketing and sales. Eric has led high-performance teams at Cochlear and Abbott, driving numerous global product launches and significant revenue growth. Notably he played an instrumental role in the world's most successful medical device, the continuous glucose monitor Freestyle Libre, now generating over $5B in annual sales for Abbott. Eric is leading the next phase of Microba's global medical diagnostics go-to-market strategy and growth.

Appointment of Chief Product Officer – Chris Saad

Chris is a renowned product leader with 25 years experience building high-growth companies in Australia and Silicon Valley. A sought-after advisor globally in product leadership and organisation design, product strategy and product management. Notably, Chris was a product leader at Uber during its critical growth years.

Financial Update

Unaudited revenue for the September 2024 quarter totalled $3.65m, representing 239% growth vs PCP with Personal Testing & Supplements up 316% to $3.39m, and Research Testing down 1% to $0.26m. Cash receipts for the September 2024 quarter totalled $5.07m, up 184% vs PCP.

As at 30 September 2024, Microba had $16.4m in cash or equivalents, which does not include the approximately $6m relating to the Company's FY24 R&D Tax Incentive which was lodged during the quarter and is expected to be received in H1 FY25.

In accordance with Listing Rule 4.7C, payments made during the quarter to related parties and their associates included in item 6.1 of Appendix 4C was $164,574 and included Director fees.

This announcement has been authorised for release by the Board.

[12] Miyauchi, Eiji, et al. "The impact of the gut microbiome on extra-intestinal autoimmune diseases." Nature Reviews Immunology 23.1 (2023): 9-23.
[13] De Luca, F. and Shoenfeld, Y. The microbiome in autoimmune diseases. Clin Exp Immunol. (2019). https://doi.org/10.1111/cei.13158.
[14] Fugger, L.et al. Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. Cell. (2020). https://doi.org/10.1016/j.cell.2020.03.007https://doi.org/10.1016/j.cell.2020.03.007.
[15] https://www.prnewswire.com/news-releases/global-autoimmune-treatment-market-soars-to-288-32-billion-by-2028--driven-by-a-7-72-cagr-from-2023--301909189.html

ASX Announcement
29 October 2024

For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Microba Life Sciences Limited, and controlled entities	
ABN	**Quarter ended ("current quarter")**
82 617 096 652	30 September 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	5,067	5,067
1.2	Payments for		
	(a) research and development	(520)	(520)
	(b) product manufacturing and operating costs	(2,159)	(2,159)
	(c) advertising and marketing	(260)	(260)
	(d) leased assets	(241)	(241)
	(e) staff costs	(3,902)	(3,902)
	(f) administration and corporate costs	(1,798)	(1,798)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	240	240
1.5	Interest and other costs of finance paid	(24)	(24)
1.6	Income taxes paid	(5)	(5)
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(3,602)**	**(3,602)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(1,387)	(1,387)
	(d) investments	-	-
	(e) intellectual property	(520)	(520)
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(1,907)**	**(1,907)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,298	1,298
3.6	Repayment of borrowings	(253)	(253)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**1,046**	**1,046**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	20,890	20,890
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,602)	(3,602)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,907)	(1,907)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,046	1,046

Consolidated statement of cash flows		Current quarter $A'000	Year to date $A'000
4.5	Effect of movement in exchange rates on cash held	(1)	(1)
4.6	**Cash and cash equivalents at end of period**	**16,426**	**16,426**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	15,426	20,890
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)*	1,000	
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**16,426**	**20,890**

*A term deposit of $1,000,000 was classified as restricted cash as stipulated under the NovaSeqX funding agreement (referred to at Section 7 of this document). The term deposit will be held for the duration of the agreement (36 months). The term deposit rolls over every 3 months and is subject to an interest rate review on rollover.

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(165)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: Payments included in item 6.1 above relate to Director Fees and Consulting Fees paid to Directors of Microba Life Sciences Limited during the period.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	(1,441)	(1,441)
7.4	**Total financing facilities**	**(1,441)**	**(1,441)**

7.5	**Unused financing facilities available at quarter end**	0

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Insurance Premium Funding Agreement: An unsecured insurance premium funding arrangement was entered into to finance the Group's annual insurance premiums. The balance originally drawn was $494k on 25 May 2024, the balance owing at quarter end was $247k, and is repayable over 10 equal monthly instalments, with a fixed interest rate of 2.69%.

NovaSeqX Plus Funding Agreement: A funding arrangement was entered into to finance the purchase of a state-of-the-art Illumina NovaSeqX Plus sequencing machine. The funding is secured again the machine. The balance originally drawn was $1,298k on 30 July 2024, the balance owing at quarter end was $1,194k, and is repayable over 36 equal monthly instalments, with a fixed interest rate of 8.52%.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,602)
8.2	Cash and cash equivalents at quarter end (item 4.6)	16,426
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	**16,426**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**4.6**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

N/A

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
N/A	

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **29 October 2024**

Authorised by: **The Board of Directors**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.